| 2541 |
QUATREX EAR DROPS |
CLOTRIMAZOLE USP 1 % W/V, CHLORAMPHENICOL BP 5% W/V, ANHUDROUS BECLOMETHASONE DIPROPIONATE BP 0.025 % W/V, LIDOCAINE HYDROCHLORIDE BP 2% W/V |
EAR DROPS |
BOTTLE |
TO TREAT EAR INFECTIONS BY RELIEVING INFLAMMATION AND TARGETING THE BACTERIA AND FUNGI RESPONSIBLE FOR SYMPTOMS, IT CAN ALSO RELIEVE PAIN BY FUNCTIONING AS A LOCAL ANESTHETIC |
NULL |
VE PRODUCTS (LAO) CO.,LTD |
OM SAI PHARMA PACK |
INDIA |
CERTIFICATE RELEASED |
12 I 5830/24 |
16-DEC-2024 |
15-DEC-2029 |
View |
| 2542 |
RELCER |
DRIED ALUMINIUM HYDROXIDE GEL BP 250MG, MAGNESIUM HYDROXIDE USP 250MG, SIMETHICONE USP 40MG, DEGLYCYRRHIZINATED LIQUORICE 4G |
TABLET |
STRIP |
ARE USED AS AN ANTACID FOR THE SYMPTOMATIC RELIEF IN THE TREATMENT OF PEPTIC ULCER, GASTRITIS, OESOPHAGITIS, HIATUS HERNIA AND DYSPEPTIC CONDITIONS ASSOCIATED WITH HYPERACIDITY |
NULL |
VE PRODUCTS (LAO) CO.,LTD |
GLENMARK PHARMACEUTICALS LIMITED |
INDIA |
CERTIFICATE RELEASED |
02 I 2755/06 |
03-Oct-2023 |
02-Oct-2026 |
View |
| 2543 |
RELCER |
ALUMINIUM HYDROXIDE 365MG, MAGNESIUM HYDROXIDE 80MG, SIMETHICONE USP 100MG, DEGLYCYRRIZINATED LIGUORICE EQUIVALENT TO LIQUORICE 400MG |
GEL |
BOTTLE |
USE FOR SYMPTOMATIC RELIEF IN THE TREATMENT OF PEPTIC ULCER, GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD), GASTRITIS, OESOPHAGITIS AND DYSPEPTIC CONDITIONS ASSOCIATED WITH HYPERACIDITY |
NULL |
VE PRODUCTS (LAO) CO.,LTD |
GLENMARK PHARMACEUTICALS LIMITED |
INDIA |
CERTIFICATE RELEASED |
04 I 2995/08 |
03-Oct-2023 |
02-Oct-2026 |
View |
| 2544 |
SERTAVEX CREAM |
SERTACONAZOLE NITRATE BP 20 MG/G |
CREAM |
TUBE |
FOR THE TOPICAL TREATMENT OF INTERDIGITAL TINEA PEDIS IN IMMUNOCOMPETENT PATIENTS 12 YEARS OF AGE AND OLDER, CAUSED BY TRICHOPHYTON RUBRUM, TRICHOPHYTON MENTAGROPHYTES AND EPIDERMOPHYTON FLOCCOSUM. |
NULL |
VE PRODUCTS (LAO) CO.,LTD |
OM SAI PHARMA PACK |
INDIA |
CERTIFICATE RELEASED |
04 I 5734/24 |
2024-04-26 |
2027-04-25 |
View |
| 2545 |
SUPIROCIN OINTMENT |
MUPIROCIN USP 2%W/W |
OINTMENT |
TUBE |
FOR THE TOPICAL TREATMENT OF PRIMARY AND SECONDARY BACTERIAL INFECTION CAUSED BY SUSCEPTIBLE BACTERIA, INCLUDING CONDITION SUCH AS: IMPETIGO SECONDARILY INFECTED TRAUMATIC LESIONS BURNS, CELLULITES CHRONIC LEG ULCER AND EXUDATIVE VENOUS ULCERS, ALSO PROPH |
NULL |
VE PRODUCTS (LAO) CO.,LTD |
GLENMARK PHARMACEUTICALS LIMITED |
INDIA |
CERTIFICATE RELEASED |
09 I 4589/18 |
22-JUL-2022 |
21-JUL-2025 |
View |
| 2546 |
TACROVEX F OINTMENT |
TACROLIMUS USP 0.1 % W/W |
OINTMENT |
TUBE |
ADULTS AND ADOLESCENTS ( 16 YEARS OF AGE AND ABOVE) : TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN ADULTS WHO ARE NOT ADEQUATELY RESPONSIVE TO OR ARE INTOLERANT OF CONVENTIONAL THERAPIES SUCH AS TOPICAL CORTICOSTEROIDS. |
NULL |
VE PRODUCTS (LAO) CO.,LTD |
OM SAI PHARMA PACK |
INDIA |
CERTIFICATE RELEASED |
04 I 5735/24 |
2024-04-26 |
2027-04-25 |
View |
| 2547 |
TACROVEX OINTMENT |
TACROLIMUS USP 0.03 % W/W |
OINTMENT |
TUBE |
ADULTS AND ADOLESCENTS ( 16 YEARS OF AGE AND ABOVE) : TREATMENT OF MODERATE TO SEVERE ATOPIC DERMATITIS IN ADULTS WHO ARE NOT ADEQUATELY RESPONSIVE TO OR ARE INTOLERANT OF CONVENTIONAL THERAPIES SUCH AS TOPICAL CORTICOSTEROIDS. |
NULL |
VE PRODUCTS (LAO) CO.,LTD |
OM SAI PHARMA PACK |
INDIA |
CERTIFICATE RELEASED |
04 I 5736/24 |
2024-04-26 |
2027-04-25 |
View |
| 2548 |
UGESIC |
PIROXICAM BP 20MG |
TABLET |
BLISTERPACK |
ACUTE MUSCULOSKELETAL PAIN(ARTHRITIS), RENAL COLIC, MIGRAINE, DYSMENNORHEA, POST OPERATIVE PAIN, ACUTE GOUT, SPONDYLITIS, BACKACHE AND SEVERE TOOTHACHE |
NULL |
VE PRODUCTS (LAO) CO.,LTD |
MEYER ORGANICS PVT. LTD |
INDIA |
CERTIFICATE RELEASED |
12 I 3274/08 |
30-JAN-2024 |
29-JAN-2027 |
View |
| 2549 |
VAGIVEX VT1 TABLETS |
CLOTRIMAZOLE USP 500 MG |
VAGINAL TABLETS |
BLISTERPACK |
TREATMENT OF CANDIDAL VAGINITIS |
NULL |
VE PRODUCTS (LAO) CO.,LTD |
PENTA KRAFT |
INDIA |
CERTIFICATE RELEASED |
08 I 5600/23 |
05-SEP-2023 |
04-SEP-2026 |
View |
| 2550 |
VAGIVEX VT3 TABLETS |
CLOTRIMAZOLE USP 200 MG |
VAGINAL TABLETS |
BLISTERPACK |
TREATMENT OF CANDIDAL VAGINITIS |
NULL |
VE PRODUCTS (LAO) CO.,LTD |
PENTA KRAFT |
INDIA |
CERTIFICATE RELEASED |
08 I 5598/23 |
05-SEP-2023 |
04-SEP-2026 |
View |
